Accumulation of immunosuppressive CD11b+ myeloid cells correlates with the failure to prevent tumor growth in the anterior chamber of the eye

Journal of Immunology

Volumn 177, Issue 3, 2006, Pages 1599-1608

  McKenna, Kyle C ^a   Kapp, Judith A ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; OVALBUMIN; THY 1 ANTIGEN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR EYE CHAMBER DISEASE; ARTICLE; BONE MARROW CELL; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EYE TUMOR; FEMALE; FLOW CYTOMETRY; IMMUNE RESPONSE; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN; SPLEEN CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY;

EID: 33746214824     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.3.1599     Document Type: Article

References (56)

1. Albert D. M., A. S. Niffenegger, and J. K. Willson. 1992. Treatment of metastatic uveal melanoma: review and recommendations. Surv. Ophthalmol. 36: 429-438.
2. Rajpal, S., R. Moore, and C. P. Karakousis. 1983. Survival in metastatic ocular melanoma. cancer 52: 334-336.
3. Kujala, E., T. Makitie, and T. Kivela. 2003. Very long-term prognosis of patients with malignant uveal melanoma. Invest. Ophthalmol. Vis. Sci. 44: 4651-4659.
4. van Dinten, L. C., N. Pul, A. F. van Nieuwpoort, C. J. Out, M. J. Jager, and P. J. van den Elsen. 2005. Uveal and cutaneous melanoma: shared expression characteristics of melanoma-associated antigens. Invest. Ophthalmol. Vis. Sci. 46: 24-30.
5. van Duinen, S. G., D. J. Ruiter, E. B. Broecker, E. A. van der Velde, C. Sorg, K. Welcaart, and S. Ferrone. 1988. Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res. 48: 1019-1025.
6. Rosenberg S., A., J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, M. E. Dudley, S. L. Schwarz, P. J. Spiess, et al. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4: 321-327.
7. Anastassiou, G., V. Rebmann, S. Wagner, N. Bornfeld, and H. Grosse-Wilde. 2003. Expression of classic and nonclassic HLA class I antigens in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 44: 2016-2019.
8. Dithmar, S. A., D. A. Rusciano, C. A. Armstrong, M. J. Lynn, and H. E. Grossniklaus. 1999. Depletion of NK cell activity results in growth of hepatic micrometastases in a murine ocular melanoma model. Curr. Eye Res. 19: 426-431.
9. Niederkorn, J. Y., J. W. Streilein, and J. A. Shadduck. 1981. Deviant immune responses to allogeneic tumors injected intracamerally and subcutaneously in mice. Invest. Ophthalmol. Vis. Sci. 20: 355-363.
10. Medawar, P. 1948. Immunity to homologous grafted skin: III. The fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br. J. Exp. Pathol. 29: 58-69.
11. Egan, R. M., C. Yorkey, R. Black, W. K. Loh, J. L. Stevens, and J. G. Woodward. 1996. Peptide-specific T cell clonal expansion in vivo following immunization in the eye, an immune-privileged site. J. Immunol. 157: 2262-2271.
12. Perez, V. L., A. Biuckians, and J. W. Streilein. 2000. In-vivo impaired T helper 1 cell development in submandibular lymph nodes due to II-12 deficiency following antigen injection into the anterior chamber of the eye. Ocol. Immunol. Inflamm. 8: 9-24.
13. + T cells. J. Immunol. 169: 5630-5637.
14. Mizuno, K., A. F. Clark, and J. W. Streilein. 1989. Anterior chamber-associated immune deviation induced by soluble antigens. Invest. Ophthalmol. Vis. Sci. 30: 1112-1119.
15. + CTL responses. Invest. Ophthalmol. Vis. Sci. 43: 3473-3479.
16. Boonman, Z. F., G. J. van Mierlo, M. F. Fransen, K. L. Franken, R. Offringa, C. J. Melief, M. J. Jager, and R. E. Toes. 2004. Intraocular tumor antigen drains specifically to submandibular lymph nodes, resulting in an abortive cytotoxic T cell reaction. J. Immunol. 172: 1567-1574.
17. Niederkorn, J. Y., and J. W. Streilein. 1983. Alloantigens placed into the anterior chamber of the eye induce specific suppression of delayed-type hypersensitivity but normal cytotoxic T lymphocyte and helper T lymphocyte responses. J. Immunol. 131: 2670-2674.
18. Niederkorn, J. Y., and J. W. Streilein. 1984. Adoptive transfer of immunity to intraocular tumors in mice. Invest. Ophthalmol. Vis. Sci. 25: 336-342.
19. Ksander, B. R., and J. W. Streilein. 1989. Analysis of cytotoxic T cell responses to intracameral allogeneic tumors. Invest. Ophthalmol. Vis. Sci. 30: 323-329.
20. Niederkorn, J. Y., and J. W. Streilein. 1983. Intracamerally induced concomitant immunity: mice harboring progressively growing intraocular tumors are immune to spontaneous metastases and secondary tumor challenge. J. Immunol. 131: 2587-2594.
21. Moore, M. W., F. R. Carbone, and M. J. Bevan. 1988. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 54: 777-785.
22. Robertson, J. M., P. E. Jensen, and B. D. Evavold. 2000. DO11.10 and OT-II T cells recognize a C-terminal ovalbumin 323-339 epitope. J. Immunol. 164: 4706-4712.
23. Hogquist, K. A., S. C. Jameson, W. R. Heath, J. L. Howard, M. J. Bevan, and F. R. Carbone. 1994. T cell receptor antagonist peptides induce positive selection. Cell 76: 17-27.
24. Barnden, M. J., J. Allison, W. R. Heath, and F. R. Carbone. 1998. Defective TCR expression in transgenic mice constructed using cDNA-based α- and β-chain genes under the control of heterologous regulatory elements. Immunol. Cell Biol. 76: 34-40.
25. + T cells. Science 248: 1227-1230.
26. McCarrick, J. W. III, J. R. Parnes, R. H. Seong, D. Solter, and B. B. Knowles. 1993. Positive-negative selection gene targeting with the diphtheria toxin A-chain gene in mouse embryonic stem cells. Transgenic Res. 2: 183-190.
27. +-autoreactive CTL expressing both type 1 and type 2 cytokines in C57BL/6 mice. J. Immunol. 164: 86-92.
28. Ke, Y., L. M. Kapp, and J. A. Kapp. 2003. Inhibition of tumor rejection by γδ cells and IL-10. Cell. Immunol. 221: 107-114.
29. + T cells: efficacy is limited by migration away from the site and induction of nonresponsiveness. J. Immunol. 162: 2858-2866.
30. Clark, A. F., J. Mellon, X. Y. Li, D. Ma, H. Leher, R. Apte, H. Alizadeh, S. Hegde, A. McLenaghan, E. Mayhew, et al. 1999. Inhibition of intraocular tumor growth by topical application of the angiostatic steroid anecortave acetate. Invest. Ophthalmol. Vis. Sci. 40: 2158-2162.
31. + T lymphocytes. Invest. Ophthalmol. Vis. Sci. 34: 3622-3634.
32. Lagasse, E., and I. L. Weissman. 1996. Flow cytometric identification of murine neutrophils and monocytes. J. Immunol. Methods 197: 139-150.
33. + myeloid cells. J. Immunol. 166: 5398-5406.
34. Rodriguez, P. C., D. G. Quiceno, J. Zabaleta, B. Ortiz, A. H. Zea, M. B. Piazuelo, A. Delgado, P. Correa, J. Brayer, E. M. Sotomayor, et al. 2004. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 64: 5839-5849.
35. + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 11: 6713-6721.
36. Terabe, M., S. Matsui, J. M. Park, M. Mamura, N. Noben-Trauth, D. D. Donaldson, W. Chen, S. M. Wahl, S. Ledbetter, B. Pratt, et al. 2003. Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J. Exp. Med. 198: 1741-1752.
37. Sinha, P., V. K. Clements, and S. Ostrand-Rosenberg. 2005. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J. Immunol. 174: 636-645.
38. Ksander, B. R., and J. W. Streilein. 1989. Recovery of activated cytotoxic T cells from minor H incompatible tumor graft rejection sites. J. Immunol. 143: 426-431.
39. Ksander, B. R., and J. W. Streilein. 1990. Failure of infiltrating precursor cytotoxic T cells to acquire direct cytotoxic function in immunologically privileged sites. J. Immunol 145: 2057-2063.
40. Streilein, J. W. 2003. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat. Rev. Immunol. 3: 879-889.
41. McKenna, K. C., and J. A. Kapp. 2004. Ocular immune privilege and CTL tolerance. Immunol. Res. 29: 103-112.
42. Serafini, P., S. C. De, I. Mango, S. Cingarlini, L. Dolcetti, G. Gallina, P. Zanovello, and V. Bronte. 2004. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol. Immunother. 53: 64-72.
43. Zea, A. H., P. C. Rodriguez, M. B. Atkins, C. Hernandez, S. Signoretti, J. Zabaleta, D. McDermott, D. Quiceno, A. Youmans, A. O'Neill, et al. 2005. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 65: 3044-3048.
44. Almand, B., J. I. Clark, E. Nikitina, J. van Beynen, N. R. English, S. C. Knight, D. P. Carbone, and D. I. Gabrilovich. 2001. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 166: 678-689.
45. Kusmartsev, S., and D. I. Gabrilovich. 2005. STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J. Immunol. 174: 4880-4891.
46. Bronte, V., and P. Zanovello. 2005. Regulation of immune responses by L-arginine metabolism. Nat. Rev. Immunol. 5: 641-654.
47. + T cells by a mechanism requiring cell contact and mediated by both the cell-associated form of TNF and nitric oxide. J. Immunol 167: 5583-5593.
48. Rodriguez, P. C., A. H. Zea, J. DeSalvo, K. S. Culotta, J. Zabaleta, D. G. Quiceno, J. B. Ochoa, and A. C. Ochoa. 2003. L-arginine consumption by macrophages modulates the expression of CD3 ζ-chain in T lymphocytes. J. Immunol. 171: 1232-1239.
49. Liversidge, J., A. Dick, and S. Gordon. 2002. Nitric oxide mediates apoptosis through formation of peroxynitrite and Fas/Fas-ligand interactions in experimental autoimmune uveitis. Am. J. Pathol. 160: 905-916.
50. Gregory, M. S., A. C. Repp, A. M. Holhbaum, R. R. Saff, A. Marshak-Rothstein, and B. R. Ksander. 2002. Membrane Fas ligand activates innate immunity and terminates ocular immune privilege. J. Immunol. 169: 2727-2735.
51. Whitcup, S. M., L. R. DeBarge, H. Rosen, R. B. Nussenblatt, and C. C. Chan. 1993. Monoclonal antibody against CD11b/CD18 inhibits endotoxin-induced uveitis. Invest. Ophthalmol. Vis. Sci. 34: 673-681.
52. Miyauchi, J. 1999. All-trans retinoic acid and hematopoietic growth factors regulating the growth and differentiation of blast progenitors in acute promyelocytic leukemia. Leuk. Lymphoma 33: 267-280.
53. Gregory, M. S., S. Koh, E. Huang, R. R. Saff, A. Marshak-Rothstein, S. Mukai, and B. R. Ksander. 2005. A novel treatment for ocular tumors using membrane FasL vesicles to activate innate immunity and terminate immune privilege. Invest. Ophthalmol. Vis. Sci. 46: 2495-2502.
54. + cells. J. Immunol. 161: 5313-5320.
55. Noel, W., G. Raes, G. G. Hassanzadeh, B. P. De, and A. Beschin. 2004. Alternatively activated macrophages during parasite infections. Trends Parasitol. 20: 126-133.
56. + cells) and prognosis in malignant uveal melanoma. Invest. Ophthalmol. Vis. Sci. 42: 1414-1421.